In particular, mutations in the CHIP-associated genes DNMT3A, TET2, and ASXL1 frequently persisted at a high variant allele fraction despite the clearance of other, more AML-specific mutations like NPM1 within the same AML patient in complete hematologic remission. This evidence concerns the gene TET2 and acute myeloid leukemia.